Karen Wood

Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial

Robert J. Motzer, Thomas E. Hutson, Hilary Glen et al. · The Lancet Oncology · 2015 · 929 citations

Urology, Genitourinary Cancer, Medicine +4

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)

Ana M. Molina, Thomas E. Hutson, James Larkin et al. · Cancer Chemotherapy and Pharmacology · 2013 · 86 citations · Full text

Brake response time after total knee arthroplasty

Jeffery L. Pierson, D. R. Earles, Karen Wood · The Journal of Arthroplasty · 2003 · 79 citations

Orthopaedics, Brake Response Time, Orthopedic Biomechanics +3

A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors

L. Rhoda Molife, Emma Dean, Montserrat Blanco-Codesido et al. · Clinical Cancer Research · 2014 · 29 citations

Methods for determining key components in a mathematical model for tumor–immune dynamics in multiple myeloma

Jill Gallaher, Kamila Larripa, Marissa Renardy et al. · Journal of Theoretical Biology · 2018 · 22 citations

Cancer Immunosurveillance, Engineering, Immunology +11